Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Leben
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Anästhesie Nachrichten

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Anästhesie Nachrichten 1/2022

18.02.2022 | DFP-Fortbildung

Update SARS-CoV-2 Behandlungsempfehlungen für die Intensivmedizin

verfasst von: Dr. Markus Köstenberger, Prim. Univ.-Prof. Dr. Walter Hasibeder, Dr. Daniel Dankl, Prim. Univ.-Prof. Dr. Philip Eisenburger, Prim. Univ.-Doz. Dr. Reinhard Germann, Dr. Wilhelm Grander, Prim. Assoc. Prof. Dr. Christoph Hörmann, Univ.-Prof. Dr. Michael Joannidis, Univ.-Prof. Dr. Klaus Markstaller, Dr. Steve-Oliver Müller-Muttonen, Dr. Stefan Neuwersch-Sommeregger, PD Dr. Bettina Pfausler, Dr. Otmar Schindler, Dr. Gregor Schittek, Assoc. Prof. PD Dr. Eva Schaden, Univ.-Prof. Dr. Thomas Staudinger, Ao. Univ.-Prof. Dr. Roman Ullrich, Dr. Matthias Urban, PhD, Univ.-Prof. Dr. Andreas Valentin, MBA, Prim. Univ.-Prof. Dr. Rudolf Likar

Erschienen in: Anästhesie Nachrichten | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Auszug

Der Anteil von SARS-CoV-2-positiven Patient*innen, die intensivmedizinisch betreut werden müssen, stellen eine große Herausforderung für das medizinische und pflegerische Personal dar. Aktuelle Guidelines unterstützen mit evidenzbasierten Empfehlungen den Umgang mit COVID-19-Patient*innen im intensivmedizinischen Setting, um die maximale Sicherheit der Patient*innen und des medizinischen Betreuungsteams gleichermaßen sicherzustellen. …
Vorheriger Artikel Landiolol bei Vorhofflimmern nach herzchirurgischen Eingriffen
Literatur
1.
Köstenberger M, Hasibeder W, Dankl D, et al. SARS-CoV-2: recommendations for treatment in intensive care medicine. Wien Klin Wochenschr. 2020;132(21–22):664–70. PubMedPubMedCentral
2.
Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–e34. PubMed
3.
Kluge StJU, Welte T, et al. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19. AWMF Online. 2021.
4.
Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911–9. PubMedPubMedCentral
5.
Wang Y, Liao B, Guo Y, et al. Clinical Characteristics of Patients Infected With the Novel 2019 Coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis. 2020;7(6):ofaa187. PubMedPubMedCentral
6.
RKI. Epidemiologischer Steckbrief zu SARS-CoV‑2 und COVID-19. 2021.
7.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. PubMed
8.
Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;323(15):1499–500. PubMed
9.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42. PubMed
10.
WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021.
11.
Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82. PubMed
12.
Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181.e6. PubMed
13.
Oliveira E, Parikh A, Lopez-Ruiz A, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS ONE. 2021;16(3):e249038. PubMedPubMedCentral
14.
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. PubMed
15.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479–90. PubMedPubMedCentral
16.
Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016;35:200–5. PubMed
17.
Nasa P, Azoulay E, Khanna AK, et al. Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. Crit Care. 2021;25(1):106. PubMedPubMedCentral
18.
Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199(11):1368–76. PubMed
19.
Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis. J Crit Care. 2021;66:102–8. PubMedPubMedCentral
20.
Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. PubMed
21.
22.
NIH. Covid-19 treatment guidelines. 2021.
23.
24.
Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–18. PubMedPubMedCentral
25.
Hirsch JS, Ikizler TA, Sharma S, Mohammed A. Acute kidney injury and advanced kidney disease in the COVID-19 pandemic: proceedings from a national kidney foundation symposium. Kidney Med. 2021;3(3):426–32. PubMedPubMedCentral
26.
Joannidis M, Forni LG, Klein SJ, et al. Lung-kidney interactions in critically ill patients: consensus report of the acute disease quality initiative (ADQI) 21 workgroup. Intensive Care Med. 2020;46(4):654–72. PubMed
27.
Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747–64. PubMedPubMedCentral
28.
Investigators I, Sadeghipour P, Talasaz AH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–30.
29.
Investigators R‑C, Investigators AC‑a, Investigators A, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89.
30.
Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176–90. PubMedPubMedCentral
31.
Consortium WHOST, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
32.
WHO. WHO COVID-19 solidarity therapeutics trial. 2021.
33.
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18.
34.
de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117(12):6771–6. PubMedPubMedCentral
35.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–9. PubMedPubMedCentral
36.
Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV‑2 infections. Int J Antimicrob Agents. 2020;55(4):105933. PubMedPubMedCentral
37.
Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV‑2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.
38.
Pruijssers AJ, George AS, Schafer A, et al. Remdesivir inhibits SARS-coV‑2 in human lung cells and chimeric SARS-coV expressing the SARS-coV‑2 RNA polymerase in mice. Cell Rep. 2020;32(3):107940. PubMedPubMedCentral
39.
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. PubMedPubMedCentral
40.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71. PubMedPubMedCentral
41.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383(19):1813–26. PubMed
42.
Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541. PubMedPubMedCentral
43.
Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
44.
Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–76. PubMed
45.
Investigators R‑C, Gordon AC, Mouncey PR, et al. Interleukin‑6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–502.
46.
Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45.
47.
Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–15. PubMed
48.
Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021;9(12):1349-1351.
49.
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. PubMed
50.
51.
Metadaten
Titel
Update SARS-CoV-2 Behandlungsempfehlungen für die Intensivmedizin
verfasst von
Dr. Markus Köstenberger
Prim. Univ.-Prof. Dr. Walter Hasibeder
Dr. Daniel Dankl
Prim. Univ.-Prof. Dr. Philip Eisenburger
Prim. Univ.-Doz. Dr. Reinhard Germann
Dr. Wilhelm Grander
Prim. Assoc. Prof. Dr. Christoph Hörmann
Univ.-Prof. Dr. Michael Joannidis
Univ.-Prof. Dr. Klaus Markstaller
Dr. Steve-Oliver Müller-Muttonen
Dr. Stefan Neuwersch-Sommeregger
PD Dr. Bettina Pfausler
Dr. Otmar Schindler
Dr. Gregor Schittek
Assoc. Prof. PD Dr. Eva Schaden
Univ.-Prof. Dr. Thomas Staudinger
Ao. Univ.-Prof. Dr. Roman Ullrich
Dr. Matthias Urban, PhD
Univ.-Prof. Dr. Andreas Valentin, MBA
Prim. Univ.-Prof. Dr. Rudolf Likar
Publikationsdatum
18.02.2022
Verlag
Springer Vienna
Erschienen in
Anästhesie Nachrichten / Ausgabe 1/2022
Print ISSN: 2617-2127
Elektronische ISSN: 2731-3972
DOI
https://doi.org/10.1007/s44179-022-00019-9

Weitere Artikel der Ausgabe 1/2022

Anästhesie Nachrichten 1/2022 Zur Ausgabe

Editorial

Editorial

ÖGARI INFORMATION KOMPAKT

Präoperative Evaluierung von Kindern

Kongressbericht: Kongresstage Anästhesie & Intensivmedizin

Perioperatives Management älterer Menschen

Freies Thema

Erfahrene Teams noch besser machen – Anästhesiologisches Notfallmanagement mit eGENA

Bericht

OPG-Stellungnahmen zum Sterbeverfügungsgesetz und Palliativfonds

Bericht

Anämiemanagement im perioperativen Setting